Insulin Sensitization Therapy and the Heart: Focus on Metformin and Thiazolidinediones

Heart Failure Clinics

Volumn 8, Issue 4, 2012, Pages 539-550

  Wong, Aaron K F ^a   Struthers, Allan D ^a   Choy, Anna Maria J ^a   Lang, Chim C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chronic heart failure; Insulin resistance; Metformin; Thiazolidinedione

Indexed keywords

ANTIDIABETIC AGENT; CARVEDILOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE; METFORMIN; MINERALOCORTICOID RECEPTOR; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE;

ANIMAL MODEL; CARDIAC PATIENT; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SENSITIZATION; DRUG USE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HAZARD RATIO; HEART; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES;

EID: 84866616996     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2012.06.002     Document Type: Review

References (98)

1. Ingelsson E., Sundstrom J., Arnlov J., et al. Insulin resistance and risk of congestive heart failure. JAMA 2005, 294:334-341.
2. Tenenbaum A., Motro M., Fisman E.Z., et al. Functional class in patients with heart failure is associated with the development of diabetes. Am J Med 2003, 114:271-275.
3. Swan J.W., Anker S.D., Walton C., et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997, 30:527-532.
4. Suskin N., McKelvie R.S., Burns R.J., et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 2000, 21:1368-1375.
5. AlZadjali M.A., Godfrey V., Khan F., et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol 2009, 53:747-753.
6. Tassone F., Gianotti L., Rolfo F., et al. B-type natriuretic peptide levels and insulin resistance in patients with severe ischemic myocardial dysfunction. J Endocrinol Invest 2009, 32:805-809.
7. Doehner W., Rauchhaus M., Ponikowski P., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005, 46:1019-1026.
8. Berry C., Brett M., Stevenson K., et al. Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure. Heart 2008, 94:296-304.
9. Witteles R.M., Fowler M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008, 51:93-102.
10. Wong A.K., AlZadjali M.A., Choy A.M., et al. Insulin resistance: a potential new target for therapy in patients with heart failure. Cardiovasc Ther 2008, 26:203-213.
11. Anderson E.A., Hoffman R.P., Balon T.W., et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991, 87:2246-2252.
12. Gaboury C.L., Simonson D.C., Seely E.W., et al. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest 1994, 94:2295-2300.
13. Wisniacki N., Taylor W., Lye M., et al. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005, 91:32-37.
14. Berdichevsky A., Guarente L., Bose A. Acute oxidative stress can reverse insulin resistance by inactivation of cytoplasmic JNK. J Biol Chem 2010, 285:21581-21589.
15. Sartori M., Ceolotto G., Papparella I., et al. Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. Am J Hypertens 2004, 17:604-610.
16. Kosmala W., Jedrzejuk D., Derzhko R., et al. Left ventricular function impairment in patients with normal weight obesity: contribution of abdominal fat deposition, profibrotic state, reduced insulin sensitivity and proinflammatory activation. Circ Cardiovasc Imaging 2012, 5(3):349-356.
17. Sokos G.G., Nikolaidis L.A., Mankad S., et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
18. Avogaro A., Nosadini R., Doria A., et al. Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Physiol 1990, 258:E606-E618.
19. Chiu H.C., Kovacs A., Ford D.A., et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001, 107:813-822.
20. Park T.S., Yamashita H., Blaner W.S., et al. Lipids in the heart: a source of fuel and a source of toxins. Curr Opin Lipidol 2007, 18:277-282.
21. Vikramadithyan R.K., Hirata K., Yagyu H., et al. Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther 2005, 313:586-593.
22. Neubauer S., Horn M., Cramer M., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997, 96:2190-2196.
23. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007, 356:1140-1151.
24. Tuunanen H., Engblom E., Naum A., et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006, 12:644-652.
25. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
26. Kemppainen J., Tsuchida H., Stolen K., et al. Insulin signalling and resistance in patients with chronic heart failure. J Physiol 2003, 550:305-315.
27. Beck-da-Silva L., Higginson L., Fraser M., et al. Effect of orlistat in obese patients with heart failure: a pilot study. Congest Heart Fail 2005, 11:118-123.
28. Scheen A.J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004, 64:2537-2565.
29. Potter B.J., LeLorier J. Effect of ramipril on the incidence of diabetes. N Engl J Med 2007, 356:522-523. author reply: 523-4.
30. McMurray J.J., Holman R.R., Haffner S.M., et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1477-1490.
31. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292:2227-2236.
32. Torp-Pedersen C., Metra M., Charlesworth A., et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol or Metoprolol European Trial (COMET). Heart 2007, 93:968-973.
33. Luther J.M., Luo P., Kreger M.T., et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 2011, 54:2152-2163.
34. Swaminathan K., Davies J., George J., et al. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008, 51:762-768.
35. Yamaji M., Tsutamoto T., Kawahara C., et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. Am Heart J 2010, 160:915-921.
36. Arase Y., Suzuki F., Suzuki Y., et al. Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. J Med Virol 2009, 81:1584-1590.
37. Kahn C.R., Chen L., Cohen S.E. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000, 106:1305-1307.
38. Vasudevan A.R., Balasubramanyam A. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004, 6:850-863.
39. Diep Q.N., El Mabrouk M., Cohn J.S., et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002, 105:2296-2302.
40. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296:2572-2581.
41. Furuse Y., Ogino K., Shimoyama M., et al. Ca(2+)-sensitizing effect is involved in the positive inotropic effect of troglitazone. Br J Pharmacol 2001, 133:1307-1313.
42. Tsuji T., Mizushige K., Noma T., et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001, 38:868-874.
43. Asakawa M., Takano H., Nagai T., et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002, 105:1240-1246.
44. Caglayan E., Stauber B., Collins A.R., et al. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes 2008, 57:2470-2479.
45. Shoghi K.I., Finck B.N., Schechtman K.B., et al. In vivo metabolic phenotyping of myocardial substrate metabolism in rodents: differential efficacy of metformin and rosiglitazone monotherapy. Circ Cardiovasc Imaging 2009, 2:373-381.
46. Baranowski M., Blachnio-Zabielska A., Zabielski P., et al. Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability. Arch Biochem Biophys 2008, 477:86-91.
47. Cittadini A., Napoli R., Monti M.G., et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes 2012, 61(4):944-953.
48. Bajaj M., Baig R., Suraamornkul S., et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010, 95:1916-1923.
49. van der Meer R.W., Rijzewijk L.J., de Jong H.W., et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009, 119:2069-2077.
50. Dargie H.J., Hildebrandt P.R., Riegger G.A., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007, 49:1696-1704.
51. St John Sutton M., Rendell M., Dandona P., et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002, 25:2058-2064.
52. Giles T.D., Miller A.B., Elkayam U., et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail 2008, 14:445-452.
53. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
54. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191-1201.
55. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195.
56. Lincoff A.M., Wolski K., Nicholls S.J., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
57. McEvoy B. Pioglitazone and rosiglitazone cardiovascular safety meta-analysis. Presented at Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Gaithersburg, July 13-14, 2010. Available at: Accessed January 23, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224739.pdf.
58. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007, 370:1129-1136.
59. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
60. Wertz D.A., Chang C.L., Sarawate C.A., et al. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 2010, 3:538-545.
61. Gallagher A.M., Smeeth L., Seabroke S., et al. Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. PLoS One 2011, 6:e28157.
62. Zimmet P. Addressing the insulin resistance syndrome: a role for the thiazolidinediones. Trends Cardiovasc Med 2002, 12:354-362.
63. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004, 27:256-263.
64. Erdmann E., Wilcox R.G. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008, 29:12-20.
65. Karalliedde J., Buckingham R., Starkie M., et al. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006, 17:3482-3490.
66. Dagenais G.R., Gerstein H.C., Holman R., et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008, 31:1007-1014.
67. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007, 357:28-38.
68. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
69. Simo R., Rodriguez A., Caveda E. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Curr Drug Saf 2010, 5:234-244.
70. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann Intern Med 2002, 137:25-33.
71. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
72. Misbin R. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care 2002, 25:2244-2248.
73. Salpeter S.R., Greyber E., Pasternak G.A., et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003, 163:2594-2602.
74. Lalau J., Race J. Lactic acidosis in metformin-treated patients: prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999, 20:377-384.
75. Stades A., Heikens J., Erkeleens D., et al. Metformin and lactic acidosis: cause or coincidence? a review of case reports. J Intern Med 2004, 255:179-187.
76. Emslie-Smith A.M., Boyle D.I., Evans J.M., et al. Contraindications to metformin therapy in patients with type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet Med 2001, 18:483-488.
77. Masoudi F.A., Inzucchi S.E., Wang Y., et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111:583-590.
78. Eurich D.T., McAlister F.A., Blackburn D.F., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335:497.
79. Misbin R.I. Evaluating the safety of diabetes drugs: perspective of a Food and Drug Administration insider. Diabetes Care 2005, 28:2573-2576.
80. Shah D.D., Fonarow G.C., Horwich T.B. Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. J Card Fail 2010, 16:200-206.
81. MacDonald M.R., Eurich D.T., Majumdar S.R., et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010, 33:1213-1218.
82. Roussel R., Travert F., Pasquet B., et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010, 170:1892-1899.
83. Aguilar D., Chan W., Bozkurt B., et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011, 4:53-58.
84. Inzucchi S.E., Masoudi F.A., Wang Y., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005, 28:1680-1689.
85. Romero S.P., Andrey J.L., Garcia-Egido A., et al. Metformin therapy and prognosis of patients with heart failure and new-onset diabetes mellitus. A propensity-matched study in the community. Int J Cardiol 2011, [Epub ahead of print].
86. Shaw J.S., Wilmot R.L., Kilpatrick E.S. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007, 24:1160-1163.
87. Eurich D.T., Tsuyuki R.T., Majumdar S.R., et al. Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials 2009, 10:12.
88. Mather K.J., Verma S., Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001, 37:1344-1350.
89. Li S.N., Wang X., Zeng Q.T., et al. Metformin inhibits nuclear factor kappaB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits. Heart Vessels 2009, 24:446-453.
90. Hou X., Song J., Li X.N., et al. Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res Commun 2010, 396:199-205.
91. Ashrafian H., Frenneaux M.P., Opie L.H. Metabolic mechanisms in heart failure. Circulation 2007, 116:434-448.
92. Bertrand L., Ginion A., Beauloye C., et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol 2006, 291:H239-H250.
93. Wang X.F., Zhang J.Y., Li L., et al. Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clin Exp Pharmacol Physiol 2011, 38:94-101.
94. Sasaki H., Asanuma H., Fujita M., et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009, 119:2568-2577.
95. Gundewar S., Calvert J.W., Jha S., et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res 2009, 104:403-411.
96. Davis B.J., Xie Z., Viollet B., et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006, 55:496-505.
97. Finck B.N., Kelly D.P. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 2007, 115:2540-2548.
98. Hallsten K., Virtanen K.A., Lonnqvist F., et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med 2004, 21:1280-1287.